Publication
High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients.
Y Lisa Hwa, Dragan Jevremovic, Karen Pak, Prashant Kapoor, Alissa Visram, Morie A Gertz, David D Dingli, Francis K Buadi, Ronald S Go, Rahma Warsame, Nelson Leung, Wilson I Gonsalves, Miriam A Hobbs, Amie L Fonder, Joselle M Cook, Moritz Binder, Suzanne R Hayman, Taxiarchis Kourelis, S Vincent Rajkumar, Angela Dispenzieri, Shaji K Kumar, Eli Muchtar
- Source
- PubMed
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260916-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Iron deficiency (ID) is often overlooked in patients with haematological malignancies due to other potential aetiologies. Daratumumab, an anti-cluster of differentiation 38 (anti-CD38) monoclonal antibody, is commonly used for treating multiple myeloma (MM) in the upfront and relapsed/refractory…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available